马法兰在视网膜母细胞瘤治疗中的应用  

Application of melphalan for retinoblastoma

作　　者：刘忆南 魏文斌[1] 

机构地区：[1]首都医科大学附属北京同仁医院北京同仁眼科中心眼内肿瘤诊治研究北京市重点实验室眼科学与视觉科学北京市重点实验室,100730

出　　处：《国际眼科纵览》2016年第3期187-191,共5页International Review of Ophthalmology

基　　金：北京市自然科学基金（7112031）;国家自然科学基金（81272981）;北京市卫生系统高层次卫生技术人才培养计划（2009-3-32）

摘　　要：马法兰（melphalan）是目前治疗视网膜母细胞瘤（retinoblastoma，RB）较有效的药物，主要给药方式是经眼动脉化疗和玻璃体腔注药治疗。经眼动脉化疗后70．O％的患者在2年内无不良事件发生，并且因其全身毒性小而得到广泛应用。在RB的治疗中，对出现玻璃体种植者的治疗具有挑战性。在玻璃体腔注射马法兰技术出现后，对有玻璃体种植的RB保留眼球率远远超过了既往的任何治疗手段。因此马法兰经眼动脉化疗和玻璃体腔注药治疗是治疗RB的有效手段之一。Melphalan is the most effective drug in curing retinoblastoma （RB） currently. At pres- ent, the mainstream drug delivery mode is intraarterial chemotherapy and intravitreal injection. No adverse events happened in 70% of the patients who received intraarterial chemotherapy within two years. Because there has been hardly any systemic toxicity reported, intraarterial chemotherapy of melphalan is now widely used. Curing vitreous seeds is the most challenging part in the treatment of RB. However, when the technic of intravitreal injection of melphalan appears, the eyeball salvage rate of RB with vitreous seeds is surpassing any of the treating methods before. Therefore, intraarterial chemotherapy and intravitreal injection of melpha- lan are safe and effective ways to cure RB.

关 键 词：马法兰 视网膜母细胞瘤 玻璃体腔注射 经动脉化疗 

分 类 号：R739.7[医药卫生—肿瘤]